Category: Inside BIO Industry Analysis
Treating and Curing Disease Through Human Genome Editing
DNA defines who we are. And like anything else, sometimes there are mistakes – mutations …
Don't Leave the Highly Prevalent Chronic Diseases Behind
There is a lot to be excited about in biotech right now as we are …
Anything Could Happen at #BIO2018 Start-up Stadium
Last year Jerry Feitelson was accepted into BIO’s Start-up Stadium at the annual BIO International …
Notable Limitations of the Latest Drug Pricing Report
In a new report, Sen. Claire McCaskill, the ranking Democratic lawmaker on the Senate Homeland …
National Nutrition Month: The Promise of Gene Editing
One of the leading voices at the intersection of cooking and nutrition is Monica Reinagel …
#MakeHistory: Highlighting History | Taiwan
As one of the many economies inspired by the 1980s Biotech Revolution, Taiwan has adapted …
New Report Series Launched on The State of Innovation in Highly Prevalent Chronic Diseases
BIO’s Industry Analysis team has released its first report in a new series on the …
Patients Are at Core of Personalized Medicine Era
This week the Patient and Health Advocacy Summit concluded its sixth consecutive year, bringing hundreds …
Antimicrobial Resistance – 2017 BIO Investor Forum to Address Current Status
Alarm bells have been sounding for some time that deadly infections are developing resistance to …
"GMO Free Water"? Don't be Fooled by Misleading Labels
A recent article by Brandon McFadden in The Conversation dove into the food labeling craze, explaining how …